Item Name:Huperzine A extract powder
Test Method: HPLC
Specifications: Huperzine A 1% 5% 98% by HPLC
Molecular Formula: C15H18N2O
Molecular Mass: 242.316
CAS No.: 120786-18-7
About Huperzine A:
Huperzine A has been proven superior to drugs licensed for the treatment of Alzheimer's,including the leading anticholine sterase drugs physostigmine and tacrine. Huperzine A improved learning and memory in mice better than tacrine. Unlike physostigmine and tacrine, Huperzine A acts specifically on Ache in the brain rather than Ache found elsewhere in the body i.e., far less is wasted on irrelevat effects. Unlike physostigmine and tacrine, Huperzine A does notappear to bind to receptors in the central nervous system, which can cause adverse side efects. Itseffects last 10 to 12 times longer than physostigmine and tacrine (up to 8 hours).
Huperzine A Function:
1.Huperzine can improve memory, thinking, and behavioral function in people with Alzheimer's disease, multi-infarct dementia, and senile dementia, and increase the level of the neurotransmitter acetylcholine by blocking its breakdown.
2. It may also protect neurons from cell death caused by toxic levels of glutamate and protect against some of the effects of chemical nerve agents used in warfare,such as soman.
3.It is also the treatment of AD in a randomized controlled trial of its effect on cognitive function.
Huperzine A Application:
2. Treat parkinsonism
3.Relive Chronic headache
4. Cure tristimania
5. Improve sleep quality
6. Memory improvement
Specification of Huperzine-A:
Brown Powder (1%,5% HPLC)
White powder (98%,99% HPLC)
|Appearance||Brown or white powder||conforms|
|Particle Size||NLT 100% Through 80 mesh||conforms|
|Loss on Drying||<2.0%||0.47%|
|Total Heavy Metals||≤10ppm||conforms|
|Total Plate Count||≤1000cfu/g||conforms|
|Total Yeast & Mold||≤100cfu/g||conforms|
Bei D, Tang X, He X (2000) Curr Med Chem 7:355–374
Howes MJ, Perry NS, Houghton PJ (2003) Phytother Res 17:1–18.
Ye JW, Cai JX, Wang LM, Tang XC (1999) J Pharmacol Exp Ther 288:814–819
Zangara A (2003) Pharmacol Biochem Behav 75:675–686.
Lallement G, Baille V, Baubichon D, Carpentier P, Collombet JM, Filliat P, Foquin A, Four E, Masqueliez C, Testylier G, Tonduli L, Dorandeu F (2002) Neurotoxicology 23:1–5.
Ye JC, Zeng S, Zhang WG, Chen GS (2005) J Chromatogr B Analyt Technol Biomed Life Sci 817:187–191.
Qian BC, Wang M, Zhou ZF, Chen K, Zhou RR, Chen GS (1995) Zhongguo Yao Li Xue Bao 16:396–398
Wei GL, Xiao SH, Lu R, Liu CX (2006) J Chromatogr B Analyt Technol Biomed Life Sci 830:120–125.
Ye JC, Zeng S, Zhang GL, Chen GS (2008) Int J Pharm 356:187–192
Yue P, Tao T, Zhao Y, Ren JF, Chai XY (2007) J Pharm Biomed Anal 44:309–312.
Chu DF, Liu WH, Li YX, Li PF, Gu JK, Liu K (2006) Planta Med 72:552–555.
Fu XD, Ping QN, Gao YL, Guo JF (2004) J China Pharm Univ 35:235–238
Liu X, Li D, Wang XL, Chen CL (2006) Fudan Univ J Med Sci 33:247–250
Li YX, Jiang XH, Lan K, Wang L (2007) Biomed Chromatogr 21:15–20.
Li C, Du FF, Yu C, Xu X, Zheng J, Xu F, Zhu DY (2004) Rapid Commun Mass Spectrom 18:651–656.
Wang YW, Chu DF, Gu JK, Fawcett JP, Wu Y, Liu WH (2004) J Chromatogr B Analyt Technol Biomed Life Sci 803:375–378.
Li W, Li JH, Hu Q (2008) Biomed Chromatogr 22:354–360.
Hameda AB, Taborsky P, Pena-Mendez EM, Havel J (2007) Talanta 72:780–784.
Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), May 2001